“BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY: AN EFFECTIVE ASTHMA TREATMENT OPTION?” C. VOGELMEIER, A. D’URZO, R. PAUWELS, J.M. MERINO, M. JASPAL, S. BOUTET, I. NAYA AND D. PRICE. EUR RESPIR J 2005; 26: 819–828.

Unfortunately, in the above paper, figure 4⇓ was printed incorrectly and should have appeared as follows.

The authors have also reported a change in the Results, Overall study drug use section. The sentence “The total mean daily ICS dose in patients with high as­needed use (>4 inhalations·day⁻¹) was: budesonide 910 μg·day⁻¹ (BDP equivalent 1,420 μg·day⁻¹) versus fluticasone 701 μg·day⁻¹ (BDP equivalent 1,402μg·day⁻¹)” should read “The total mean daily ICS dose in patients with high as­needed use (>4 inhalations·week⁻¹) was: budesonide 910 μg·day⁻¹ (BDP equivalent 1,420 μg·day⁻¹) versus fluticasone 701 μg·day⁻¹ (BDP equivalent 1,402 μg·day⁻¹)”. The authors apologise for this error.

• Download figure
• Open in new tab
• Download powerpoint

Fig. 4—

The proportion of patients in the last 2 weeks of the study using a) low levels of as-needed medication (a maximum of 4 as-needed inhalations·week⁻¹) or b) higher levels (>4 as-needed inhalations·week⁻¹). Data are split by the average daily maintenance inhaled corticosteroid (ICS) dose, defined by guidelines [18] as: low or moderate dose, or high dose (for fluticasone patients only). SAL/FLU: salmeterol/fluticasone; BUD/FORM: budesonide/formoterol. ▒: high maintenance ICS dose; : moderate maintenance ICS dose; □: low maintenance ICS dose. ^#: n = 688; ^¶: n = 787; ⁺: n = 350; ^§: n = 247.